{"DataElement":{"publicId":"5209691","version":"1","preferredName":"Cellular Therapy Product Manufacture Location Pharmaceutical Company And/Or Biotechnology Company Name","preferredDefinition":"A description of the pharmaceutical and or biotechnology company where the cellular therapy product was manufactured.","longName":"5109093v1.0:5209679v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5109093","version":"1","preferredName":"Cellular Therapy Product Manufacture Location","preferredDefinition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy._A thing produced by or resulting from a process. EXAMPLE(S): drug, device. The FDA list of regulated products: animal and human drugs; therapeutic biologics; allergenics; cell, tissue and gene therapy products; blood components; blood derivative products; devices; and animal (pets and livestock) and human food/feed (medicated and un-medicated); cosmetics; pet treats; and dietary supplements._The act of making something (a product) from raw materials._A position, site, or point in space where something can be found.","longName":"5109091v1.0:2240715v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5109091","version":"1","preferredName":"Cellular Therapy Product Manufacture","preferredDefinition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.:The end result of a manufacturing process; anything that is produced.:The act of making something (a product) from raw materials.","longName":"C70601:C51980:C43360","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Product","conceptCode":"C51980","definition":"The end result of a manufacturing process; anything that is produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Manufacture","conceptCode":"C43360","definition":"The act of making something (a product) from raw materials.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A2D8463-3748-D86C-E050-BB89AD433553","latestVersionIndicator":"Yes","beginDate":"2016-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-25","modifiedBy":"ONEDATA","dateModified":"2016-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2240715","version":"1","preferredName":"Location","preferredDefinition":"A position, site, or point in space where something can be found.","longName":"C25341","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Location","conceptCode":"C25341","definition":"A position, site, or point in space where something can be found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAB2D8EC-6B99-68CB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-07-06","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2A2D8463-3756-D86C-E050-BB89AD433553","latestVersionIndicator":"Yes","beginDate":"2016-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-25","modifiedBy":"HARTLEYG","dateModified":"2023-06-28","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5209679","version":"1","preferredName":"Pharmaceutical Company And/Or Biotechnology Company Name","preferredDefinition":"A company licensed to discover, develop, market and distribute drugs._Used to indicate that either or both of two items or options may be valid._The field devoted to applying the techniques of biochemistry, cellular biology, biophysics, and molecular biology to addressing issues related to human beings and the environment._Any formal business entity for profit, which may be a corporation, a partnership, association or individual proprietorship._The words or language units by which a thing is known.","longName":"5209679v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other pharmaceutical company","valueDescription":"Other Drug Company","ValueMeaning":{"publicId":"5209680","version":"1","preferredName":"Other Drug Company","longName":"5209680","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A company licensed to discover, develop, market and distribute drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Drug Company","conceptCode":"C54149","definition":"A company licensed to discover, develop, market and distribute drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-9124-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FAC7A9C-913D-8D23-E050-BB89AD430CBC","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","deletedIndicator":"No"},{"value":"Blue Bird Biotec","valueDescription":"Bluebird Bio","ValueMeaning":{"publicId":"5209681","version":"1","preferredName":"Bluebird Bio","longName":"5209681","preferredDefinition":"A clinical-stage biotechnology company using gene therapy, cancer immunotherapy, and gene editing to treat and cure genetic diseases and cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bluebird Bio","conceptCode":"C126407","definition":"A clinical-stage biotechnology company using gene therapy, cancer immunotherapy, and gene editing to treat and cure genetic diseases and cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-9149-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FAC7A9C-9162-8D23-E050-BB89AD430CBC","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","deletedIndicator":"No"},{"value":"Kite Pharma","valueDescription":"Kite Pharma","ValueMeaning":{"publicId":"5209682","version":"1","preferredName":"Kite Pharma","longName":"5209682","preferredDefinition":"A clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products with a primary focus on engineered autologous T cell therapy designed to restore the immune system's ability to recognize and eliminate tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kite Pharma","conceptCode":"C126406","definition":"A clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products with a primary focus on engineered autologous T cell therapy designed to restore the immune system's ability to recognize and eliminate tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-916E-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FAC7A9C-9187-8D23-E050-BB89AD430CBC","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","deletedIndicator":"No"},{"value":"Celgene","valueDescription":"Celgene","ValueMeaning":{"publicId":"5209683","version":"1","preferredName":"Celgene","longName":"5209683","preferredDefinition":"An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celgene","conceptCode":"C126405","definition":"An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-9193-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FAC7A9C-91AC-8D23-E050-BB89AD430CBC","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","deletedIndicator":"No"},{"value":"Juno Therapeutics","valueDescription":"Juno Therapeutics","ValueMeaning":{"publicId":"5209684","version":"1","preferredName":"Juno Therapeutics","longName":"5209684","preferredDefinition":"A clinical-stage company developing cellular immunotherapies based on Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juno Therapeutics","conceptCode":"C126404","definition":"A clinical-stage company developing cellular immunotherapies based on Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-91B8-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FAC7A9C-91D1-8D23-E050-BB89AD430CBC","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","deletedIndicator":"No"},{"value":"Novartis","valueDescription":"Novartis","ValueMeaning":{"publicId":"5209685","version":"1","preferredName":"Novartis","longName":"5209685","preferredDefinition":"A Swiss multinational pharmaceutical company that is engaged in the development, manufacturing, and marketing of healthcare products.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Novartis","conceptCode":"C126403","definition":"A Swiss multinational pharmaceutical company that is engaged in the development, manufacturing, and marketing of healthcare products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-91DD-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2FAC7A9C-91F6-8D23-E050-BB89AD430CBC","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","deletedIndicator":"No"},{"value":"Atara Biotherapeutics","valueDescription":"Atara Biotherapeutics","ValueMeaning":{"publicId":"5838487","version":"1","preferredName":"Atara Biotherapeutics","longName":"5838487","preferredDefinition":"A privately-held drug development company that is developing cancer treatments based on allogeneic cytotoxic T lymphocyte immunotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atara Biotherapeutics","conceptCode":"C134822","definition":"A privately-held drug development company that is developing cancer treatments based on allogeneic cytotoxic T lymphocyte immunotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"506D806C-20E8-5352-E053-F662850A0D9E","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"506D806C-2101-5352-E053-F662850A0D9E","beginDate":"2017-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-26","modifiedBy":"ONEDATA","dateModified":"2017-05-26","deletedIndicator":"No"},{"value":"Bellicum Pharmaceuticals","valueDescription":"Bellicum Pharmaceuticals","ValueMeaning":{"publicId":"5838488","version":"1","preferredName":"Bellicum Pharmaceuticals","longName":"5838488","preferredDefinition":"A biopharmaceutical company focused on developing cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bellicum Pharmaceuticals","conceptCode":"C134823","definition":"A biopharmaceutical company focused on developing cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"506D806C-210D-5352-E053-F662850A0D9E","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"506D806C-2126-5352-E053-F662850A0D9E","beginDate":"2017-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-26","modifiedBy":"ONEDATA","dateModified":"2017-05-26","deletedIndicator":"No"},{"value":"Mesoblast","valueDescription":"Mesoblast Limited","ValueMeaning":{"publicId":"5838489","version":"1","preferredName":"Mesoblast Limited","longName":"5838489","preferredDefinition":"An Australian biotechnology company that is developing a proprietary technology platform based on allogeneic mesenchymal lineage adult stem cells (MLCs) to target inflammatory ailments, cardiovascular disease, and back pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesoblast Limited","conceptCode":"C134824","definition":"An Australian biotechnology company that is developing a proprietary technology platform based on allogeneic mesenchymal lineage adult stem cells (MLCs) to target inflammatory ailments, cardiovascular disease, and back pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"506D806C-2132-5352-E053-F662850A0D9E","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"506D806C-214B-5352-E053-F662850A0D9E","beginDate":"2017-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-26","modifiedBy":"ONEDATA","dateModified":"2017-05-26","deletedIndicator":"No"},{"value":"Miltenyi Biotec","valueDescription":"Miltenyi Biotec","ValueMeaning":{"publicId":"6941576","version":"1","preferredName":"Miltenyi Biotec","longName":"6941576","preferredDefinition":"A global provider of products and services associated with advance biomedical research and cellular therapy that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Miltenyi Biotec","conceptCode":"C164151","definition":"A global provider of products and services associated with advance biomedical research and cellular therapy that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92B327B0-E928-4F62-E053-F662850AE40D","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-09-17","modifiedBy":"ONEDATA","dateModified":"2019-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92B327B0-E941-4F62-E053-F662850AE40D","beginDate":"2019-09-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-09-17","modifiedBy":"ONEDATA","dateModified":"2019-09-17","deletedIndicator":"No"},{"value":"Janssen Pharmaceuticals","valueDescription":"Janssen Pharmaceuticals","ValueMeaning":{"publicId":"6942224","version":"1","preferredName":"Janssen Pharmaceuticals","longName":"6942224","preferredDefinition":"A pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas. The company conducts research and development into oncology, mental illness, neurological disorders, gastrointestinal disorders, fungal infection, and allergies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Janssen Pharmaceuticals","conceptCode":"C164191","definition":"A pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas. The company conducts research and development into oncology, mental illness, neurological disorders, gastrointestinal disorders, fungal infection, and allergies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92DE6BA3-7F66-265C-E053-F662850AC25D","latestVersionIndicator":"Yes","beginDate":"2019-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"92DE6BA3-7F7F-265C-E053-F662850AC25D","beginDate":"2019-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-09-19","modifiedBy":"ONEDATA","dateModified":"2019-09-19","deletedIndicator":"No"},{"value":"Iovance Biotherapeutics","valueDescription":"Iovance Biotherapeutics","ValueMeaning":{"publicId":"7482856","version":"1","preferredName":"Iovance Biotherapeutics","longName":"7482856","preferredDefinition":"A biopharmaceutical company working to develop tumor-infiltrating lymphocyte therapies against cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iovance Biotherapeutics","conceptCode":"C175541","definition":"A biopharmaceutical company working to develop tumor-infiltrating lymphocyte therapies against cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2A9EF44-2314-0CDD-E053-4EBD850AAD5B","latestVersionIndicator":"Yes","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2A9EF44-232D-0CDD-E053-4EBD850AAD5B","beginDate":"2020-10-27","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-27","modifiedBy":"ONEDATA","dateModified":"2020-10-27","deletedIndicator":"No"},{"value":"Daiichi Sankyo","valueDescription":"Daiichi Sankyo","ValueMeaning":{"publicId":"7477444","version":"1","preferredName":"Daiichi Sankyo","longName":"7477444","preferredDefinition":"A global pharmaceutical company committed to the development of innovative new and generic medicines, and new methods of drug discovery and delivery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daiichi Sankyo","conceptCode":"C175540","definition":"A global pharmaceutical company committed to the development of innovative new and generic medicines, and new methods of drug discovery and delivery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B25A5821-4F8D-6F8A-E053-4EBD850A3D77","latestVersionIndicator":"Yes","beginDate":"2020-10-23","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-23","modifiedBy":"ONEDATA","dateModified":"2020-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B25A5821-4FA6-6F8A-E053-4EBD850A3D77","beginDate":"2020-10-23","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-23","modifiedBy":"ONEDATA","dateModified":"2020-10-23","deletedIndicator":"No"},{"value":"Vertex","valueDescription":"Vertex Pharmaceuticals","ValueMeaning":{"publicId":"7742847","version":"1","preferredName":"Vertex Pharmaceuticals","longName":"7742847","preferredDefinition":"A global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. They are developing small molecule medicines as well as genetic and cell therapies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vertex Pharmaceuticals","conceptCode":"C180742","definition":"A global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. They are developing small molecule medicines as well as genetic and cell therapies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-BF25-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-BF3E-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Rocket Pharmaceuticals","valueDescription":"Rocket Pharmaceuticals","ValueMeaning":{"publicId":"7742848","version":"1","preferredName":"Rocket Pharmaceuticals","longName":"7742848","preferredDefinition":"A clinical-stage biotechnology company focusing on developing curative gene therapy treatments using adeno-associated viral vector (AAV) and lentiviral vector (LVV) approaches.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rocket Pharmaceuticals","conceptCode":"C180741","definition":"A clinical-stage biotechnology company focusing on developing curative gene therapy treatments using adeno-associated viral vector (AAV) and lentiviral vector (LVV) approaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-BF4A-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-BF63-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Orchard Therapeutics","valueDescription":"Orchard Therapeutics","ValueMeaning":{"publicId":"7742849","version":"1","preferredName":"Orchard Therapeutics","longName":"7742849","preferredDefinition":"A biopharmaceutical company that uses ex vivo autologous gene therapy to develop cures for rare and often-fatal diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orchard Therapeutics","conceptCode":"C180740","definition":"A biopharmaceutical company that uses ex vivo autologous gene therapy to develop cures for rare and often-fatal diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-BF6F-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-BF88-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Mustang Bio","valueDescription":"Mustang Bio","ValueMeaning":{"publicId":"7742850","version":"1","preferredName":"Mustang Bio","longName":"7742850","preferredDefinition":"A clinical-stage biopharmaceutical company focused on translating cell and gene therapies into potential cures for hematologic cancers, glioblastoma, and rare genetic diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mustang Bio","conceptCode":"C180739","definition":"A clinical-stage biopharmaceutical company focused on translating cell and gene therapies into potential cures for hematologic cancers, glioblastoma, and rare genetic diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-BF94-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-BFAD-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Graphite Bio","valueDescription":"Graphite Bio","ValueMeaning":{"publicId":"7742851","version":"1","preferredName":"Graphite Bio","longName":"7742851","preferredDefinition":"A clinical-stage gene-editing company using CRISPR technology and gene replacement to develop therapies to treat or cure human diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graphite Bio","conceptCode":"C180738","definition":"A clinical-stage gene-editing company using CRISPR technology and gene replacement to develop therapies to treat or cure human diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-BFB9-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-BFD2-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Editas","valueDescription":"Editas Medicine","ValueMeaning":{"publicId":"7742852","version":"1","preferredName":"Editas Medicine","longName":"7742852","preferredDefinition":"A clinical-stage biotechnology company which is developing gene-edited therapies based on CRISPR/Cas9 technology, using both in vivo and ex vivo modalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Editas Medicine","conceptCode":"C180737","definition":"A clinical-stage biotechnology company which is developing gene-edited therapies based on CRISPR/Cas9 technology, using both in vivo and ex vivo modalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-BFDE-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-BFF7-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"CRISPR","valueDescription":"CRISPR Therapeutics","ValueMeaning":{"publicId":"7742853","version":"1","preferredName":"CRISPR Therapeutics","longName":"7742853","preferredDefinition":"A gene editing company focused on developing gene-based medicines and therapies using its proprietary CRISPR/Cas9 platform.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CRISPR Therapeutics","conceptCode":"C180736","definition":"A gene editing company focused on developing gene-based medicines and therapies using its proprietary CRISPR/Cas9 platform.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-C003-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-C01C-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Beam","valueDescription":"Beam Therapeutics","ValueMeaning":{"publicId":"7742854","version":"1","preferredName":"Beam Therapeutics","longName":"7742854","preferredDefinition":"A biotechnology company developing precision genetic therapies through base editing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beam Therapeutics","conceptCode":"C180735","definition":"A biotechnology company developing precision genetic therapies through base editing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-C028-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-C041-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Avrobio","valueDescription":"Avrobio","ValueMeaning":{"publicId":"7742855","version":"1","preferredName":"Avrobio","longName":"7742855","preferredDefinition":"A clinical-stage biotechnology company that is developing lentivirus-based gene therapies designed to halt or reverse disease with a single dose, with a focus on lysosomal disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avrobio","conceptCode":"C180734","definition":"A clinical-stage biotechnology company that is developing lentivirus-based gene therapies designed to halt or reverse disease with a single dose, with a focus on lysosomal disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-C04D-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-C066-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"},{"value":"Aruvant","valueDescription":"Aruvant Sciences","ValueMeaning":{"publicId":"7742856","version":"1","preferredName":"Aruvant Sciences","longName":"7742856","preferredDefinition":"A clinical-stage biopharmaceutical company that is developing and commercializing gene therapies for rare diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aruvant Sciences","conceptCode":"C180733","definition":"A clinical-stage biopharmaceutical company that is developing and commercializing gene therapies for rare diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C744BF9F-C072-5EDE-E053-4EBD850A4F93","latestVersionIndicator":"Yes","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C744BF9F-C08B-5EDE-E053-4EBD850A4F93","beginDate":"2021-07-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-07-16","modifiedBy":"ONEDATA","dateModified":"2021-07-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435032","version":"1","preferredName":"Property or Attribute","preferredDefinition":"The distinguishing qualities or prominent aspect of a person, object, action, process, or substance.","longName":"C20189","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-8321-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5209678","version":"1","preferredName":"Drug Company And/Or Biotechnology Company Name","preferredDefinition":"A company licensed to discover, develop, market and distribute drugs.:Used to indicate that either or both of two items or options may be valid.:body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful; alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus.:Any formal business entity for profit, which may be a corporation, a partnership, association or individual proprietorship.:The words or language units by which a thing is known.","longName":"5209678v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Drug Company","conceptCode":"C54149","definition":"A company licensed to discover, develop, market and distribute drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Biotechnology","conceptCode":"C16351","definition":"The field devoted to applying the techniques of biochemistry, cellular biology, biophysics, and molecular biology to addressing issues related to human beings and the environment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Company","conceptCode":"C54131","definition":"Any formal business entity for profit, which may be a corporation, a partnership, association or individual proprietorship.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-90FA-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"ONEDATA","dateModified":"2016-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-910B-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"MALUMK","dateModified":"2021-07-16","changeDescription":". Added 3 PVs for 4006. AK 5/26/17. Added PV for 4003r4. 10/23/2020 KMM. Added PV for 4003r4. 10/27/2020 KMM. PVs added for 2003r1. 07/16/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685478","version":"1","longName":"Testing Set – Moderately Different","context":"NCIP"}]}],"AlternateNames":[{"name":"CTI_CTPI_pharm_biotech_com_nm","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_DIM_pharm_biotech_com_nm","type":"NMDP_FN","context":"NHLBI"},{"name":"Organization:name","type":"HCT_BRIDG_5","context":"NHLBI"},{"name":"CTP_CPS_pharm_biotech_com_nm","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the name of the phar","type":"Preferred Question Text","description":"What was the name of the pharmaceutical and or biotechnology company where the cellular therapy product was manufactured?","url":null,"context":"NHLBI"},{"name":"Specify pharmaceutical / biotech company","type":"Alternate Question Text","description":"Specify pharmaceutical / biotech company","url":null,"context":"NHLBI"},{"name":"Specify pharmaceutical / biotech company","type":"Application Standard Question Text","description":"Specify pharmaceutical / biotech company","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FAC7A9C-92B7-8D23-E050-BB89AD430CBC","latestVersionIndicator":"Yes","beginDate":"2016-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-04-04","modifiedBy":"KUMMEROA","dateModified":"2019-11-20","changeDescription":"Added HCT_BRIDG5 alternate name - RR 2018-12-23","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}